Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children
MT newswire2026/10/09 18:0102:01 PM EDT, 10/09/2026 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) said Friday that new interim data from an open-label extension study evaluating Alyftrek in cystic fibrosis showed that some pediatric patients aged 2 to 5 years recovered exocrine pancreatic function, allowing them to discontinue pancreatic enzyme replacement therapy. Of 48 children enrolled in the pancreatic enzyme replacement therapy discontinuation substudy, 18, or 37.5%, stopped the therapy for a mean of 8.6 weeks after at least 48 weeks of treatment, the company said. Across the full 66-child cohort, 50% were not on the therapy at the time of the data cut, Vertex said. Price: 510.01, Change: +6.76, Percent Change: +1.34
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Edges Higher as Treasury Yields, Dollar Ease -- Market Talk
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
Crypto prices
More
